vtp-27999
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01217736)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ReninINHIBITOR
REN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)C[C@H]1CCCOC1- Mol. weight
- 525.09 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1276678 ↗
Also known as
- methyl (2-((3-chlorophenyl)(1-((2-(methylamino)-3-(tetrahydro-2h-pyran-3-yl)propyl)carbamoyl)piperidin-3-yl)methoxy)ethyl)carbamate
- vtp-000027999
- vtp-27999
- vtp-27999
- vtp-27999
- vtp-27999
- vtp-27,999
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01217736 | Phase 1 | Sep 1, 2010 | Harvard University, Vitae Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Vitae Pharmaceuticals | For profit | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1